The combined diagnostic model, integrating blood routine parameters (e.g., WBC, NLR, LMR) and tumor markers (e.g., AFP, CA19-9), demonstrates high clinical operability due to its reliance on routinely available and cost-effective tests. The gene discussed is AFP; the disease is neoplasm.